Logo image of MYMD

MYMD PHARMACEUTICALS INC (MYMD) Stock Fundamental Analysis

NASDAQ:MYMD - Nasdaq - US62856X2018 - Common Stock - Currency: USD

1.82  0 (0%)

Fundamental Rating

2

Taking everything into account, MYMD scores 2 out of 10 in our fundamental rating. MYMD was compared to 194 industry peers in the Pharmaceuticals industry. While MYMD seems to be doing ok healthwise, there are quite some concerns on its profitability. MYMD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MYMD had negative earnings in the past year.
In the past year MYMD has reported a negative cash flow from operations.
In the past 5 years MYMD always reported negative net income.
In the past 5 years MYMD always reported negative operating cash flow.
MYMD Yearly Net Income VS EBIT VS OCF VS FCFMYMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -5M -10M -15M -20M -25M

1.2 Ratios

MYMD's Return On Assets of -32.43% is in line compared to the rest of the industry. MYMD outperforms 51.55% of its industry peers.
The Return On Equity of MYMD (-43.95%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -32.43%
ROE -43.95%
ROIC N/A
ROA(3y)-84.95%
ROA(5y)-85.91%
ROE(3y)-93.54%
ROE(5y)-101.66%
ROIC(3y)N/A
ROIC(5y)N/A
MYMD Yearly ROA, ROE, ROICMYMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MYMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MYMD Yearly Profit, Operating, Gross MarginsMYMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -200 -400 -600

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, MYMD has more shares outstanding
There is no outstanding debt for MYMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MYMD Yearly Shares OutstandingMYMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
MYMD Yearly Total Debt VS Total AssetsMYMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M

2.2 Solvency

MYMD has an Altman-Z score of -7.99. This is a bad value and indicates that MYMD is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of MYMD (-7.99) is worse than 73.20% of its industry peers.
There is no outstanding debt for MYMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.99
ROIC/WACCN/A
WACCN/A
MYMD Yearly LT Debt VS Equity VS FCFMYMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 1.71 indicates that MYMD should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.71, MYMD is doing worse than 71.65% of the companies in the same industry.
A Quick Ratio of 1.71 indicates that MYMD should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.71, MYMD is doing worse than 67.53% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.71
Quick Ratio 1.71
MYMD Yearly Current Assets VS Current LiabilitesMYMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M

More info and screens

0

3. Growth

3.1 Past

MYMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.63%, which is quite impressive.
EPS 1Y (TTM)52.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%166.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MYMD Yearly Revenue VS EstimatesMYMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M 4M 5M
MYMD Yearly EPS VS EstimatesMYMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 -5K -10K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MYMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MYMD Price Earnings VS Forward Price EarningsMYMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MYMD Per share dataMYMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

MYMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MYMD PHARMACEUTICALS INC

NASDAQ:MYMD (7/23/2024, 8:26:03 PM)

1.82

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2024-05-13/bmo
Earnings (Next)08-12 2024-08-12/amc
Inst Owners2.93%
Inst Owner Change-69.04%
Ins Owners88.61%
Ins Owner Change0%
Market Cap4.20M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.26
P/tB 0.75
EV/EBITDA N/A
EPS(TTM)-0.18
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-5.76
FCFYN/A
OCF(TTM)-5.76
OCFYN/A
SpS0
BVpS6.97
TBVpS2.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.43%
ROE -43.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-84.95%
ROA(5y)-85.91%
ROE(3y)-93.54%
ROE(5y)-101.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.71
Quick Ratio 1.71
Altman-Z -7.99
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%166.67%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.2%
OCF growth 3YN/A
OCF growth 5YN/A